anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medicinal shampoo comprises the gamma isomer of benzene hexachloride and a shampoo vehicle which comprises one or more detergents and an opacifying and/or thickening agent.  Specified detergents are sodium lauryl sulphate, triethanolamine lauryl sulphate, cetrimide, the condensate of octyl cresol and 8-10 molecular proportions of ethylene oxide, and lauric acid diethanolamide.  Specified opacifying and/or thickening agents are spermaceti, cetanol, cetostearyl alcohol, stearic acid, sodium stearate and carboxymethylcellulose.  Glycerol, propylene glycol, diacetone alcohol, arachis oil, liquid paraffin, and terpineol may also be present.  The shampoo may be in the form of a cream, paste, gel or liquid cream.ALSO:Pharmaceutical compositions comprise the gamma isomer of benzene hexachloride and a shampoo vehicle which comprises one or more detergents and an opacifying and/or thickening agent. Specified detergents are sodium lauryl sulphate, triethanolamine lauryl sulphate, cetrimide, the condensate of octyl cresol and 8-10 molecular proportions of ethylene oxide, lauric acid diethanolamide.  Specified thickening and/or opacifying agents are spermaceti, cetanol, cetosterayl alcohol, stearic acid, sodium stearate and carboxymethyl cellulose.  Glycerol, propylene glycol, diacetone alcohol, arachis oil, liquid paraffin and terpineol may also be present.  The composition may be in the form of a cream, paste, gel or liquid cream.
Therapeutic interventions in health care require the use of resources. Since these resources are limited, it is important for clinical decision-makers to have economic information in addition to safety and efficacy data. In the economic environment of health care today, the incremental costs for a new therapeutic intervention must be offset by the value associated with better outcomes such as improved health and health-related quality of life and/or lower health care utilization costs over time.

Questions about the cost and effectiveness of medical care have generated considerable attention in medical outcomes research. In 1993, the Department of Health and Human Services appointed a multi-disciplinary group to recommend standards for the evaluation of health care. The panel's report suggested that standardized outcomes analyses be conducted to evaluate the cost-effectiveness of medical care. These analyses require preference-weighted measures of health-related quality of life. Such measures are needed in order to adjust survival time for health-related quality of life.
The present invention relates to application of gentiopicrin as an effective ingredient to preparing medicine for restraining hepatitis B viruses. Gentiopicrin as an effective ingredient is a compound which is prepared from a generally-used traditional Chinese medicine of largeleaf gentian roots in China through extraction and separation. The gentiopicrin as an effective ingredient in a preparation is mixed with a pharmacologically acceptable carrier, such as organic or inorganic solid or liquid excipient which is suitable for administration inside and outside stomachs and intestines. The medicinal preparation can be in solid forms, such as tablets, capsules, medicinal powder, pills and granules, and can also be in liquid forms, such as injections, emulsion, etc. The gentiopicrin is prepared into injections. Pharmacodynamic experiments show that a duck infected by duck hepatitis B viruses is treated by gentiopicrin medicine through intramuscular injection on the seventh day, and the gentiopicrin medicine has obvious effect on restraining the level of the blood serum DHBV-DNA of the infected duck with the dosage of two times every day in group of 200 mg/kg by 10-day administration. Statistical treatment results have very obvious differences with suppression of P<0.01 to 0.05, and the restraining effect of three-time experiments can be repeated.
The present invention discloses an antibacterial peptide, a preparation method and applications thereof. The antibacterial peptide is a porcine lactoferrin peptide LFP-20 or a reconstruction antibacterial peptide LF-2 or a reconstruction antibacterial peptide LF-6. The antibacterial peptide preparation method comprises adopting a solid phase chemical synthesis method or a genetic engineering expression technology to clone encoding gene of the antibacterial peptide to a vector, and then expressing in host cells to obtain the antibacterial peptide, wherein engineering bacterial used in the genetic engineering expression technology is genetic engineering bacteria P.pastorisSMD1168, and an expression vector is an eukaryotic expression vector PICZalphaA. The invention further relates to an application of the antibacterial peptide in preparation of drugs for treatments of gram-positive bacteria or gram-negative bacteria infectious diseases. With the reconstruction antibacterial peptide, in vitro bacterial killing activity and bacterial killing speed of the LFP-20 can be increased, and permeability of the LFP-20 on inner membranes and outer membranes of bacterial can be enhanced so as to enhance bacterial killing capability of the LFP-20. The reconstruction antibacterial peptide LF-2 and the reconstruction antibacterial peptide LF-6 further have strong in vivo bacteria removing capability. The present invention further relates to a method for expressing the recombinant reconstruction antibacterial peptide LF-6 by using pichia pastoris yeast. According to the present invention, the process is simple, and the product has significant bacterial inhibition activity.
Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
Although patients with hyperuricemia and gout often have dyslipidemia, the effects of febuxostat, a xanthine oxidase inhibitor, on their lipid profiles are unclear. Thus, we performed a sub-analysis of the randomized PRIZE study in which the effects of febuxostat on carotid atherosclerosis were investigated in patients with hyperuricemia. The participants were randomized to the febuxostat or control group. The primary endpoint of this sub-analysis was changes in the patients' non-high-density lipoprotein cholesterol (HDL-C) levels from baseline to 6-month follow-up. Correlations between the changes in lipid profiles and cardiometabolic parameters were also evaluated. In total, 456 patients were included. From baseline to 6 months, non-HDL-C levels were significantly reduced in the febuxostat group (-5.9 mg/dL, 95% confidence interval [CI]: -9.1 to -2.8 mg/dL, p < 0.001), but not in the control group (-1.3 mg/dL, 95% CI: -4.4 to 1.8, p = 0.348). The reduction in non-HDL-C levels was more pronounced in women and correlated with changes in serum uric acid and estimated glomerular filtration rate levels only in the febuxostat group. In patients with hyperuricemia, febuxostat treatment was associated with reduced non-HDL-C levels from baseline to the 6-month follow-up compared to the control treatment, suggesting that the lipid-lowering effect of febuxostat should be considered when targeting dyslipidemia.
Pesticides have been pointed out as hormone disruptors and may significantly affect the prognosis of hormone-dependent diseases such as breast cancer (BC). Here, we investigated the impact of occupational pesticide exposure on systemic cortisol levels in female rural workers diagnosed with BC. Occupational exposure was assessed by interviews with a standardized questionnaire. Plasma samples (112 from pesticide-exposed women and 77 from unexposed women) were collected in the afternoon, outside the physiological cortisol peak, and analyzed by a chemiluminescent paramagnetic immunoassay for the quantitative determination of cortisol levels in serum and plasma. The results from both groups were categorized according to patients' clinicopathological and exposure data. BC pesticide-exposed women presented higher levels of cortisol than the unexposed. Higher cortisol levels were also detected in the exposed group with more aggressive disease (triple-negative BC), with tumors over 2 cm, with lymph node metastases, and with high risk of disease recurrence and death. These findings demonstrated that there is an association between pesticide exposure and BC that affected cortisol levels and correlated to poor disease prognosis.
Acute hyperglycemia is a transient increase in plasma glucose level (PGL) frequently observed in patients with ST-elevation myocardial infarction (STEMI). The aim of this review is to clarify the molecular mechanisms whereby acute hyperglycemia impacts coronary flow and myocardial perfusion in patients with acute myocardial infarction (AMI) and to discuss the consequent clinical and prognostic implications. We conducted a comprehensive literature review on the molecular causes of myocardial damage driven by acute hyperglycemia in the context of AMI. The negative impact of high PGL on admission recognizes a multifactorial etiology involving endothelial function, oxidative stress, production of leukocyte adhesion molecules, platelet aggregation, and activation of the coagulation cascade. The current evidence suggests that all these pathophysiological mechanisms compromise myocardial perfusion as a whole and not only in the culprit coronary artery. Acute hyperglycemia on admission, regardless of whether or not in the context of a diabetes mellitus history, could be, thus, identified as a predictor of worse myocardial reperfusion and poorer prognosis in patients with AMI. In order to reduce hyperglycemia-related complications, it seems rational to pursue in these patients an adequate and quick control of PGL, despite the best pharmacological treatment for acute hyperglycemia still remaining a matter of debate.
The present invention provides methods for treating tissue to inhibit post-implant calcification of a biological tissue. In one method of this invention, a tissue is immersed in or otherwise contacted with a pretreated glutaraldehyde solution, i.e., a heat-treated or pH-adjusted glutaraldehyde solution. The tissue may be partially fixed with glutaraldehyde prior to, after, or concurrently with the step of contacting the tissue with the pretreated gluteraldehyde. Contact with the pretreated gluteraldehyde produces free amine groups on the tissue, which are subsequently blocked by contacting the crosslinked tissue with a blocking agent. In another embodiment, a tissue is contacted with either a non-pretreated glutaraldehyde or a pH-adjusted glutaraldehyde solution for a period of time sufficient to crosslink the tissue. The crosslinked tissue is then treated with a reducing agent that reduces aldehyde and carboxylic acid groups on the fixed tissue.
The use of an acrylic copolymer (I) is claimed as a coating agent for a core containing a drug (A) effective against ulcerative colitis, in the production of medicament formulation for the therapy of ulcerative colitis. (I) is derived from 50-68 wt. % methyl acrylate, 27-45 wt. % 1-4C alkyl (meth)acrylate ester and 5-20 wt. % methacrylic acid.  An Independent claim is included for a medicament formulation consisting of (A) coated with (I).
OBJECTIVE AND RESULTS DESCRIPTION: The study objective was to investigate the potential of quantitative measures of pulmonary inflammation by [18 F]Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as a surrogate marker of inflammation in COPD. Patients treated with anti-inflammatory Liraglutide were compared to placebo and correlated with inflammatory markers. 27 COPD-patients (14 receiving Liraglutide treatment and 13 receiving placebo) underwent 4D-respiratory-gated FDG-PET/CT before and after treatment. Two raters independently segmented the lungs from CT images and measured activity in whole lung, mean standard uptake values (SUVmean) corrected for lean-body-mass in the phase-matched PET images of the whole segmented lung volume, and total lesion glycolysis (TLG; SUVmean multiplied by volume). Inter-rater reliability was analyzed with Bland-Altman analysis and correlation plots. We found no differences in metabolic activity in the lungs between the two groups as a surrogate of pulmonary inflammation, and no changes in inflammation markers. The purpose of the research and brief summary of main findings. The degree of and changes in pulmonary inflammation in chronic obstructive pulmonary disease (COPD) may be difficult to ascertain. Measuring metabolic activity as a surrogate marker of inflammation by FDG-PET/CT may be useful, but data on its use in COPD including reproducibility is still limited, especially with respiration-gated technique, which should improve quantification in the lungs. We assessed several quantitative measures of metabolic activity and correlated them with inflammation markers, and we assessed reproducibility of the methods. We found no differences in metabolic activity between the two groups (before and after 40 weeks treatment with Liraglutide vs. placebo). Bland-Altman analysis showed good agreement between the two raters.
TRIAL REGISTRATION: The study was conducted between February 2018 and March 2020 at the Department of Pulmonary Diseases at Hospital South West Jutland and Lillebaelt Hospital, Denmark, and registered from March 2018 at clinicaltrials.gov with trial registration number NCT03466021.
BACKGROUND: Total joint replacement for osteoarthritis is one of the most successful surgical procedures in modern medicine. However, aseptic loosening continues to be a leading cause of revision arthroplasty. The diagnosis of aseptic loosening remains a challenge as patients are often asymptomatic until the late stages. MicroRNA (miRNA) has been demonstrated to be a useful diagnostic tool and has been successfully used in the diagnosis of other diseases. We aimed to identify differentially expressed miRNA in the plasma of patients with aseptic loosening.
METHODS: Adult patients undergoing revision arthroplasty for aseptic loosening and age- and gender-matched controls were recruited. Samples of bone, tissue and blood were collected, and RNA sequencing was performed in 24 patients with aseptic loosening and 26 controls. Differentially expressed miRNA in plasma was matched to differentially expressed mRNA in periprosthetic bone and tissue. Western blot was used to validate protein expression.
RESULTS: Seven miRNA was differentially expressed in the plasma of patients with osteolysis (logFC >|2|, adj-P < 0.05). Three thousand six hundred and eighty mRNA genes in bone and 427 mRNA genes in tissue samples of osteolysis patients were differentially expressed (logFC >|2|, adj-P < 0.05). Gene enrichment analysis and pathway analysis revealed two miRNA (miR-1246 and miR-6089) had multiple gene targets in the Wnt signalling pathway in the local bone and tissues which regulate bone metabolism.
CONCLUSION: These results suggest that aseptic loosening may be regulated by miR-1246 and miR-6089 via the Wnt signalling pathway.
BACKGROUND: Aberrant movement in chronic low back pain (CLBP) is associated with a deficit in the lumbar multifidus (LM) and changes in cortical topography. Anodal transcranial direct current stimulation (a-tDCS) can be used to enhance cortical excitability by priming the neuromuscular system for motor control exercise (MCE), thereby enhancing LM activation and movement control. This study aimed to determine the effects of a 6-week MCE program combined with a-tDCS on cortical topography, LM activation, movement patterns, and clinical outcomes in individuals with CLBP.
METHODS: Twenty-two individuals with CLBP were randomly allocated to the a-tDCS group (a-tDCS; n = 12) or sham-tDCS group (s-tDCS; n = 10). Both groups received 20 min of tDCS followed by 30 min of MCE. The LM and erector spinae (ES) cortical topography, LM activation, movement control battery tests, and clinical outcomes (disability and quality of life) were measured pre- and post-intervention.
RESULTS: Significant interaction (group × time; p < 0.01) was found in the distance between LM and ES cortical locations. The a-tDCS group demonstrated significantly fewer discrete peaks (p < 0.05) in both ES and LM and significant improvements (p < 0.05) in clinical outcomes post-intervention. The s-tDCS group demonstrated a significant increase (p < 0.05) in the number of discrete peaks in the LM cortical topography. No significant changes (p > 0.05) in LM activation were observed in either group; however, both groups demonstrated improved movement patterns.
DISCUSSION: Our findings suggest that combined a-tDCS with MCE can separate LM and ES locations over time while s-tDCS (MCE alone) reduces the distance. Our study did not find superior benefits of adding a-tDCS before MCE for LM activation, movement patterns, or clinical outcomes.
Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, a risk of disability or even death as the course of the disease progresses. Studies have shown that B cells can present their own antigens to autoimmune T cells to promote the release of inflammatory factors, or they can differentiate into plasma cells to release autoantibodies, and play an important role in the occurrence and progression of autoimmune diseases. In recent years, it has become a major research focus to deplete B cells in patients or inhibit B cell function. This research focuses on CAR-T cells killing B cells. This fully reflects the application prospects of CAR-T cells in autoimmune diseases.

Based on the current research progress, our center intends to conduct research on the safety and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory scleroderma
Health metrics can be received from at least one person wearing a health monitoring device in an unencumbered fashion that permits free motion. The health monitoring device can wirelessly convey the heath metrics to a remotely located computing device. The received health metrics can be compared against at least one configurable, yet previously established threshold. A change in a situation proximate to the person can be inferred based upon comparison results. A programmatic event can be fired based upon the inferred change. At least one programmatic action can be automatically initiated responsive to the firing of the programmatic event, wherein the programmatic action initiates a response to the inferred change.
Painful diabetic neuropathy (PDN) is one of the most common and intractable complications of diabetes. Painful diabetic neuropathy is characterized by neuropathic pain accompanied by dorsal root ganglion (DRG) nociceptor hyperexcitability, axonal degeneration, and changes in cutaneous innervation. However, the complete molecular profile underlying the hyperexcitable cellular phenotype of DRG nociceptors in PDN has not been elucidated. This gap in our knowledge is a critical barrier to developing effective, mechanism-based, and disease-modifying therapeutic approaches that are urgently needed to relieve the symptoms of PDN. Using single-cell RNA sequencing of DRGs, we demonstrated an increased expression of the Mas-related G protein-coupled receptor d (Mrgprd) in a subpopulation of DRG neurons in the well-established high-fat diet (HFD) mouse model of PDN. Importantly, limiting Mrgprd signaling reversed mechanical allodynia in the HFD mouse model of PDN. Furthermore, in vivo calcium imaging allowed us to demonstrate that activation of Mrgprd-positive cutaneous afferents that persist in diabetic mice skin resulted in an increased intracellular calcium influx into DRG nociceptors that we assess in vivo as a readout of nociceptors hyperexcitability. Taken together, our data highlight a key role of Mrgprd-mediated DRG neuron excitability in the generation and maintenance of neuropathic pain in a mouse model of PDN. Hence, we propose Mrgprd as a promising and accessible target for developing effective therapeutics currently unavailable for treating neuropathic pain in PDN.
PURPOSE:To ensure an accurate over-reading job in the titled system by using an electrocardiogram information display means which displays the electrocardiogram information on a display and a composition/display means which retrieves automatically the past electrocardiogram information of the same person to be diagnosed for comparison and display. CONSTITUTION:An electrocardiogram information display means 1 displays the electrocardiogram information (the electrocardiogram waveforms, the person to be diagnosed, the result of diagnosis, the measured value, etc.). A comparison/ display means 2 retrieves automatically the past electrocardiogram information on the same person to be diagnosed for comparison and display. A correction means 3 corrects the result of diagnosis. A report production means 4 produces a check report and a storage means 5 stores the check results for a long period of time. In such a constitution, the information needed for diagnosis of the electrocardiogram can be quickly obtained. Thus a doctor can change the results of diagnoses, etc., on the same screen while confirming those obtained information. As a result, a fine and accurate over-reading job is carried out with high efficiency.
After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
The invention discloses epilactitol with probiotic activity and a preparation method and application thereof. The structural formula of the epilactitol is shown as a formula I. The epilactitol can be prepared from epilactose by using sodium borohydride; or prepared by taking the apparent lactose as a raw material and utilizing a palladium-carbon (Pd/C) catalyst. The test results of the present invention show that epi-lactitol promotes the production of more butyric acid by the intestinal microorganisms of the body than epi-lactose and lactitol, which indicates that epi-lactitol has better efficacy than epi-lactose and lactitol. Epitolactitol is hardly hydrolyzed in the small intestine and can reach the cecum. Indication tableLactitol has the potential to become a prebiotic.
To counteract calcium deficiency in pregnant women and their embryoes, egg-shells are washed in a 4% formaldehyde (lysoform) spray, allowed to soak in an enzymatic washing agent soln. for up to six hours, combined with another hour of mechanical agitation. This is follwed by a water rinsing stage under further agitation by a wash in 0.55% sterogenol soln. and repeated rinsing. Finally, the shells are centrifuged, dried in hot air at 105deg.C and prior to converting then into tablets or dragees. (Corrected abstract)